FMO4: A Protein Targeted for Neurodegenerative Disorders (G2329)

Target Name: FMO4

NCBI ID: G2329

FMO4: A Protein Targeted for Neurodegenerative Disorders

FMO4 (dimethylaniline oxidase 4) is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and kidneys. It is a member of the superfamily of oxidases, which are a group of enzymes that mediate the transfer of electrons from reduced molecules to oxygen, resulting in the formation of reactive oxygen species.

FMO4 is involved in the metabolism of various molecules, including neurotransmitters, such as dopamine, serotonin, and endothelium-derived relaxing factor (EDRF). It is a critical enzyme in the synthesis of these neurotransmitters, as well as in the detoxification of harmful substances such as toxins and environmental pollutants.

FMO4 is also involved in the regulation of cellular signaling pathways, including the production of reactive oxygen species that can contribute to the damage caused by oxidative stress. This is important for maintaining the health and function of cells, as chronic oxidative stress can lead to a range of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease.

Due to its involvement in the synthesis and regulation of neurotransmitters, as well as its role in the detoxification of harmful substances, FMO4 has been identified as a potential drug target. Researchers are currently exploring the use of small molecules and other compounds to modulate the activity of FMO4 and its downstream targets.

One approach to targeting FMO4 is to use inhibitors of the activity of the enzyme. These inhibitors can either inhibit the activity of FMO4 itself or target the downstream targets of FMO4 that are involved in neurotransmission. One of the most promising inhibitors of FMO4 is a compound called DMI (dimethylaniline), which is a known inhibitor of the activity of the enzyme.

DMI works by binding to the active site of FMO4 and inhibiting the activity of the enzyme. This inhibition can be irreversible and allows for the inhibition of the activity of FMO4 for a prolonged period of time. Experiments have shown that DMI can be effective in animal models of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Another approach to targeting FMO4 is to use small molecules that modulate its activity. These small molecules can either enhance or inhibit the activity of FMO4 depending on the context. One of the most promising small molecules for targeting FMO4 is a compound called EBF (Etsinic acid ), which is a known inhibitor of the activity of the enzyme.

EBF works by binding to the active site of FMO4 and inhibiting the activity of the enzyme. This inhibition can be reversible and allows for the enhancement of the activity of FMO4 under certain conditions. Experiments have shown that EBF can be effective in animal models of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to inhibitors and enhancers, researchers are also exploring the use of small molecules that regulate the expression of FMO4. This can be done by using small molecules that bind to specific transcription factors, which are proteins that regulate the expression of genes. One of the most promising small molecules for regulating FMO4 expression is a compound called miR-202, which is a known regulator of the expression of various genes, including FMO4.

miR-202 works by binding to the promoter of a gene and regulating the translation of RNA into protein. This can be done by binding to specific

Protein Name: Flavin Containing Dimethylaniline Monoxygenase 4

Functions: This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides

More Common Targets